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Abstract
Background: Medication management in residential aged care facilities is an ongoing concern. Numerous studies
have reported high rates of inappropriate prescribing and medication use in aged care facilities, which contribute
to residents’ adverse health outcomes. There is a need for new models of care that enhance inter-disciplinary
collaboration between residential aged care facility staff and healthcare professionals, to improve medication
management. Pilot research has demonstrated the feasibility and benefits of integrating a pharmacist into the aged care
facility team to improve the quality use of medicines. This protocol describes the design and methods for a cluster
randomised controlled trial to evaluate the outcomes and conduct economic evaluation of a service model where on-site
pharmacists are integrated into residential aged care facility healthcare teams to improve medication management.
Methods: Intervention aged care facilities will employ on-site pharmacists to work as part of their healthcare teams 2 to
2.5 days per week for 12 months. On-site pharmacists, in collaboration with facility nurses, prescribers, community
pharmacists, residents and families will conduct medication management activities to improve the quality use of
medicines. Aged care facilities in the control group will continue usual care. The target sample size is 1188 residents from
a minimum of 13 aged care facilities. The primary outcome is the appropriateness of prescribing, measured by the
proportion of residents who are prescribed at least one potentially inappropriate medicine according to the 2019 Beers
Criteria. Secondary outcomes include hospital and emergency department presentations, fall rates, prevalence and dose
of antipsychotics and benzodiazepines, Anticholinergic Cognitive Burden Score, staff influenza vaccination rate, time spent
on medication rounds, appropriateness of dose form modification and completeness of resident’s allergy and adverse
drug reaction documentation. A cost-consequence and cost-effectiveness analysis will be embedded in the trial.
Discussion: The results of this study will provide information on clinical and economic outcomes of a model that
integrates on-site pharmacists into Australian residential aged care facilities. The results will provide policymakers with
recommendations relevant to further implementation of this model.
Trial registration: ACTRN12620000430932. Registered on 1 April 2020 with ANZCTR
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Background
Older adults residing in residential aged care facilities
(RACFs) generally have complex co-morbidities and are
prescribed a large number of different medications [1].
Studies have reported that, on average, RACF residents
take between 9 and 11 regular medications [2–4]. Poly-
pharmacy increases the risk of medication-related prob-
lems and adverse drug events, including hospitalisations,
placing a significant burden on residents and economic
cost on the health care system [5–7]. Australian studies
have shown that almost all RACF residents have at least
one medication-related problem [4, 8–11] and between
30% and 73% of residents are prescribed at least one po-
tentially inappropriate medication (PIM) [4, 12–18]. Ac-
cording to a recent meta-analysis of 33 international
studies, the use of PIM is significantly associated with an
increased risk of hospitalisation in the older population,
and the risk was higher in those who took more than
one PIM [19]. Additionally, PIMs are associated with
other potential adverse outcomes in older indivisuals, in-
cluding fall, fracture, cognitive decline, delirium, stroke
and cardiovascular events [20, 21].
Among PIMs, sedatives, antipsychotics and drugs with
anticholinergic properties are particularly associated
with greater risk of harm. A large Australian cohort
study among 11,368 residents found that 61% were tak-
ing psychotropic medications, with the majority of these
agents having sedative properties that can contribute to
falls or confusion [22]. The over-use of psychotropic
medications has been recently highlighted in the interim
report of the Australian Royal Commission into Aged
Care Quality and Safety [23]. Australian studies have re-
ported that over 20% of RACF residents were taking an-
tipsychotics regularly [22, 24], and the duration of
antipsychotic use was longer than recommended [25–
27]. Prolonged use of antipsychotics in older people is
linked with increased risk of hospitalisation, hip fracture,
peneumonia, stroke and death [28, 29]. Another large
Australian study [30] of 17,000 RACF residents reported
that 46% were taking drugs with moderate to strong
anticholinergic effects; these drugs can contribute to
cognitive and functional decline, delirium, worsening de-
mentia, and increased mortality in older people [31].
Additionally, over-prescribing, using medicines longer
than recommended, and drug interactions affect medica-
tion safety in aged care residents. The Australian 2018
Aged Care National Antimicrobial Prescribing Survey
reported that 10% of residents were taking an antibiotic
on the day of the survey, and about two thirds of these
prescriptions were lacking relevant documentation of
sign and symptoms to justify the need for antibiotic use
[32]. Another large Australian study reported that more
than 50% of residents were prescribed proton pump in-
hibitors with a median duration of use of 360 days in the
year, while the recommended duration of use is 8 weeks
[27]. Over-prescribing can also lead to unwanted drug
interactions; a retrospective study of aged care resident’s
medication records showed that 16% of residents were
at high risk of drug-induced QT prolongation and po-
tential arrhythmia due to polypharmacy [33]. Overall,
many published studies highlight the need to improve
medication management in RACFs. It is an area where
pharmacists, doctors and nurses can work together, en-
suring improved medication safety and quality use of
medicines for residents [34].
Amongst the factors affecting medication safety and
quality use of medicines in RACFs, lack of accessibility
to pharmacists and doctors, and poor interdisciplinary
collaboration were highlighted in a recent systematic re-
view of international studies [35]. Consistent with these
findings, the Australian Medical Association highlighted
the “extremely urgent” need to increase the number of
health care professionals in RACFs [36]. General practi-
tioners (GPs), nurses and pharmacists are the key health
professionals involved in the prescribing, administration
and supply of medicines. Since these health professionals
are generally not co-located, there are significant limita-
tions in access, communication [37] and coordination of
medication management processes [1] for aged care
residents.
In Australia, there are two government-funded
pharmacist-led services in place that aim to improve
medication management in RACFs: (i) residential medi-
cation management review (RMMR) program [38] and
(ii) quality use of medicine (QUM) service [39]. The
RMMR for RACF residents has been in place since 1997
[37] and is similar to “clinical medication reviews” in the
UK, “comprehensive medication reviews” in the USA
and “MedsCheck LTC” in Canada [40–42]. The RMMR
program enables GPs to refer RACF residents to accre-
dited pharmacists to receive a medication review every
24 months or when there is a clinical need [43]. Al-
though the RMMR service has been shown to be an ef-
fective strategy to identify and resolve medication-
related problems and improve quality use of medicines
for RACF residents [2], the service has logistical limita-
tions. These include physical separation of community
pharmacies, RMMR pharmacists and RACFs which leads
Kosari et al. Trials          (2021) 22:390 Page 2 of 12
to lack of timely access to pharmacist services when resi-
dents need them most [37]. Additionally, access to clin-
ical pharmacists to conduct RMMRs for RACF residents
is limited to periodic visits to the facility. Consequently,
pharmacists performing RMMRs may not have a thor-
ough understanding of the resident and may not be fa-
miliar with the facility staff and organisational structure,
resulting in limited effectiveness of their activities within
RACFs [44]. Other limitations of RMMR include limited
involvement of pharmacists in the implementation and
follow-up of recommendations and inconsistency in the
level of collaboration between the health professionals in
the RMMR processes [45]. QUM services are funded by
the Commonwealth Department of Health for pharma-
cists to visit RACFS and conduct education to improve
practices and procedures related to medication use.
QUM services are intended to improve the medication
management at the RACF level (e.g. through audits and
staff education) [39, 46]; however, there has been little
research to explore the effectiveness of this service [37].
Integrating an on-site pharmacist as part of the
RACF health care team may address the gap in
provision of medication management practices, pol-
icies and processes. On-site pharmacists, in collabor-
ation with nurses, GPs, specialists, community
pharmacists, residents and families will conduct medi-
cation management activities to improve the quality
use of medicines at the facility [47–50]. This new
model can improve communication among the health-
care team and enhance resident and family’s involve-
ment in medication management decisions for
individuals [48], leading to improved person-centred
care. At the facility level, the on-site pharmacist can
develop and enhance RACF policies and procedures
for overall medication management [44]. These
system improvement activities include reviewing and
enhancing medication ordering, storage and adminis-
tration processes, as well as conducting staff educa-
tion, providing medication information, responding to
medication utilisation reports, developing clinical re-
ferral pathways and contributing to staff and resident
influenza vaccination.
A proposed model of integrated on-site pharmacist
services into the RACF health care team was exam-
ined in a pilot study which was conducted by the lead
author [47–51]. The conceptual foundation of the
new model was to improve multi-disciplinary care,
communication and collaboration in RACF’s health-
care team to enhance medication management [47,
48]. The findings of the pilot study indicated that the
integration of a pharmacist into a RACF was feasible
and acceptable to RACF staff, residents and GPs and
resulted in improved medication administration and
clinical documentation [47], increased provision of
education for nursing and carer staff to promote the quality
use of medicines and prevent medication administration er-
rors [48], and enhanced staff influenza vaccination rates
[49]. The positive findings of the pilot study informed the
allocation of program funds from the Australian Depart-
ment of Health to implement and evaluate this model in
RACFs in the Australian Capital Territory (ACT).
The aim of this larger study is therefore to conduct
a cluster randomised controlled trial (RCT) to evalu-
ate if integrating pharmacists into RACFs, improves
medication management in RACFs in the ACT,
Australia. Objectives of the study include determining
if this new integrated model (i) improves appropriate-
ness of prescribing for RACF residents, as determined
by the use of PIMs according to 2019 Beers Criteria
[52], (ii) reduces RACF residents’ Emergency Depart-
ment (ED) presentations and hospital admissions, (iii)
improves other quality use of medicine indicators at




This is a cluster RCT in RACFs in the ACT, Australia,
with RACFs as the unit of randomisation. Participating
RACFs will be randomised into either an intervention or
control group. RACFs in the intervention group, in
addition to ‘usual care’, will each employ an on-site
pharmacist as member of the healthcare team. RACFs in
the control group will continue ‘usual care’ that includes
receiving government funded RMMR and QUM services
from visiting pharmacists. Intervention and control
groups will be recruited and randomised in staggered
groups which will run in parallel.
Participants
RACFs
All RACFs in the ACT that are nationally accredited facil-
ities will be invited to participate in the trial. RACFs that
have less than 20 beds will be excluded. There are a total
number of 1978 RACF beds in facilities in the ACT, and
the ACT had a population of 431,000 in 2020 [53].
Residents
Permanent residents of included RACFs will be included
in the study unless they specifically request their data
not to be included in the trial. Respite (non-permanent)
residents will be excluded.
Pharmacists
Qualified pharmacists will be recruited through open ex-
pressions of interest sent to pharmacy professional
groups and associations. The selection criteria for phar-
macists include having registration with the Australian
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Health Practitioner Regulation Agency, accreditation to
conduct medication reviews by the Australian Associ-
ation of Consultant Pharmacy or equivalent hospital or
geriatric clinical pharmacy experience, and accreditation
to conduct vaccination. A list of eligible pharmacists will
be provided to the intervention RACFs, who will employ
pharmacists as per their organisational policy. Salaries
for pharmacists will be funded by the research grant;
however, they will be directly employed by RACFs as
RACF staff members.
Recruitment process
All RACFs in the ACT, Australia, that meet the inclu-
sion criteria will be invited to participate in this study.
After being provided information on the nature of the
study and data required, each RACF will agree to partici-
pate through a signed contract. Recruitment will be stag-
gered over a period of 6 months or until the sample size
achieved. The recruitment and study timelines are
shown in Fig. 1.
Randomisation and blinding
Randomisation will be at the facility level. RACFs will be
randomised into either intervention or control group
through computer-generated allocation by an independ-
ent researcher external to the research team. Random-
isation will be stratified by size of facility. Due to the
nature of the intervention, the trial participants will not
be blinded.
Intervention and model of care
RACFs in the intervention arm will have a pharmacist
employed by their organisation as part of their health
care team for 2 to 2.5 days a week for 12 months. Inter-
vention pharmacists can work in up to 2 RACFs. Phar-
macists will report to RACF managers. They will
conduct resident and facility level activities that are
within their current scope of practice as a health profes-
sional registered with Australian Health Professional
Registered Agency.
The intervention (model of care) was informed by the
findings from the pilot study [47–51] and discussion
with RACF managers, GPs, pharmacists and a consumer
representative who participated in the pilot. Compo-
nents of this model of care are informed by integration
of pharmacists into non-dispensing primacy care roles
[37, 54]. Components and how they differ from usual
care are presented in Table 1.
Pharmacist activities in intervention RACFs include
the following:
 Performing medication reviews in collaboration with
residents, families, prescribers and nurses
 Identifying residents at high risk of medication-
related harm and hospitalisation, and prioritising in-
terventions to address them
 Medication reconciliation and review at transition of
care
 Participating in case conferences with GPs, palliative
care team, families and residents
 Reviewing and optimising medication administration
rounds
 Updating and improving resident records including
clinical and care information
 Answering medication-related queries from resi-
dents, families and staff
 Conducting regular clinical audits to identify
medication-related problems
 Educating residents, families and RACF staff about
medication-related issues
 Improving the RACF’s medication management
policies and procedures
 Participating in relevant RACF committees and
meetings including Medication Advisory Committee,
Quality and Safety meetings, Falls Review
Committee, and Medication Incidents Review
Committee
 Improving influenza vaccination rates of staff and
residents
Pharmacists in intervention sites will not be permitted
to conduct RMMR or QUM services. RACFs will receive
these services from existing providers as a part of usual
care.
Pharmacist training and support
Pharmacists will participate in mandatory training before
commencing in RACFs, including an initial full-day
overview of clinical pharmacy practice in the aged care
setting, followed by a session focused on the pharma-
cist’s role in RACFs and the trial design and processes.
Pharmacists will be provided with clinical and geriatric
pharmacy resources including content on deprescribing,
psychotropics, pain management, principles of medica-
tion review in aged care, Beers Criteria [52] and wound
management.
The study team will meet face to face with pharmacists
monthly to discuss potential problems and address ques-
tions. Furthermore, pharmacists will be invited to partici-
pate in quarterly meetings held by the study team to
discuss study activities. An online Microsoft Teams will
link on-site pharmacists to each other to facilitate a com-
munity of learning to discuss issues they are experiencing.
Outcomes
All outcome measures will be collected from both inter-
vention and control RACFs and compared as below.
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Fig. 1 Study timeline
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Primary outcome
 Change in proportion of residents who are
prescribed at least one PIM (from baseline to 12
months) according to the 2019 Beers Criteria [52]
Secondary outcomes
 Rate of unplanned ED presentations and hospital
admissions per resident collected from RACF
records over 12 months
 Polypharmacy—number of regular medications
 Change in proportion of residents who are
prescribed at least one psychotropic medicine
(defined as antipsychotics and benzodiazepines),
excluding those residents with major psychiatric
diseases or epilepsy (from baseline to 12 months)
 Change in dose of psychotropic medicines
(measured as chlorpromazine or diazepam equivalent
daily dose [55] (from baseline to 12 months)
 Change in residents’ Anticholinergic Cognitive
Burden Score (ACB) [56] (from baseline to 12
months)
 Rate of staff influenza vaccination measured at the
end of influenza season, from RACF records
 Fall rate per resident, as documented from RACF
fall records over 12 months
 Change in time spent on medication administration
rounds per RACF, through observing randomly
selected medication rounds [47] (from baseline to
12 months)
 Change in appropriateness of medicine dose form
modification per RACF, through observing
randomly selected medication rounds [47] (from
baseline to 12 months)
Table 1 Key components and comparison between existing and proposed model
Key component Existing model Proposed model
Governance and service
structure
RMMR & QUM activities are conducted by independent
pharmacist (who are contractors) on visitational basis.
Pharmacist is employed by the RACF and is
incorporated into RACFs care team.





Pharmacist is not incorporated into the RACF care
team. They visit RACF at semi-regular intervals, provide
medication advice to GPs through RMMRs and provide
quality improvement projects.
Pharmacist is incorporated into the RACF care
team and has contact with residents, families,
GPs and prescribers, nurses and care staff. The
pharmacist is available on-site at RACFs and
involves residents and families into decision-
making processes to improve medication
management.
Reciprocal interdependence Pharmacist provides medication review as an add-on
service to assist GPs with quality of prescribing. How-
ever, they are not incorporated into the RACF care
teams.
Multi-disciplinary team members, including
pharmacists, nurses, carers, GPs and
prescribers, community pharmacists, residents
and families engage in shared decision
making and work together to achieve goals.
Communication Pharmacist communicates medication-related issues
about individual residents to the GPs, usually through
RMMR. GPs communicate medication changes to RACF
nurses.
Pharmacist communicates and coordinates
medication-related issues directly with GPs,
nurses, carers, residents, community pharmacy
and hospital.
Collaboration Pharmacist usually collaborates with GPs to conduct
RMMR.
Pharmacist closely collaborates on a regular
basis with nurses, aged care staff and
management, GPs and other prescribers,
visiting pharmacists, community pharmacy,
residents, families and hospital.
Sharing and access to
information
Pharmacist has limited access to residents’ clinical
records, which may include laboratory reports, while
GPs and nurses have full access to clinical records.
All team members, including the pharmacist,
will have full access to residents’ records,
current medication lists, information about
allergies, lab results, notes, procedures, and
hospital discharge summaries.
Coordinated care/outcomes Pharmacist provides once-off advice and opinion to
GPs in RMMRs (including 2 follow-ups) but are not in-
volved in implementing medication management
changes or ongoing monitoring.
Residents’ treatment goals and outcomes are
coordinated within the team of nurses, carers,
pharmacist, GPs and other service providers.
Pharmacist is involved in providing advice to
GPs, prescribers and the RACF care team, and
in implementing residents care plans and
goals of care. Pharmacist also contributes to
improving RACF medication management
policies and procedures.
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 Change in proportion of residents who have drug
allergies or adverse drug reactions documented in
their RACF records (from baseline to 12 months)
 Number of medication-related incidents over 12
months
 Cost-consequence and cost-effectiveness of the
intervention over 12 months
Data collection
Data will be collected at RACF, resident and pharmacist
levels throughout the 12-month trial period. RACFs’
characteristics (number of beds, number of permanent
residents, resident profile and number of staff) will be
collected through surveys with RACF managers. De-
identified residents’ data for outcome measures will be
collected by the research team visiting the facilities at
baseline, each month and at 12 months. Randomly se-
lected medication rounds will be observed to determine
the time spent on medication rounds and assess the ap-
propriateness of dose form modifications using the
method described earlier [47]. In case of potential
logistical limitations in light of COVID-19 and any fu-
ture restriction of access to RACFs, RACF staff will col-
lect the required data. On-site pharmacists in the
intervention group will self-report their daily activities
through an online diary using QUALTRICS. Details of
data collection items and timing are listed in Table 2.
Sample size
It was estimated that a conventional RCT with random-
isation of individuals would be able to detect a reduction
from 60 to 40% of residents having at least one PIM
[14], with a minimum of 106 residents in each arm (total
of 212 residents in both arms) with a significance level
of 5%, a power of 80% on equal allocation and a re-
sponse rate of 85%. By adjusting for the loss of power
due to clustering, with an intra-cluster correlation coeffi-
cient of 0.05 and a cluster size of 93 residents per RACF,
the estimated sample size is (1 + [(93–1) x 0.05] =5.6 x
106) or 594 residents in each arm (1188 in both arms),
equating to a minimum of 13 sites. The sample size was
calculated using G*Power 3.1.9.4 [57].
Table 2 Data collection details
Data Data collection
Facility level data
Number of permanent residents, proportion of residents with dementia, and proportion receiving the
highest level of government funding
Baseline and at 12 months
Number of RACF registered nurses rostered during day/night/weekend Baseline and at 12 months
Care staff turn-over reported by RACFs Baseline
Total number of beds and bed occupancy rate Baseline
Resident turn over Monthly
Number of medication-related incidents Monthly
Number of resident falls Monthly
Time taken to conduct medication rounds Baseline and at 12 months
% of staff/residents received influenza vaccination At one time point
% of residents that have drug allergy and adverse drug reactions documented Baseline and at 12 months
Number of GPs visiting residents in facility Baseline
RACF managers perceived top 5 reasons for unplanned hospitalisations of residents in previous 12 months,
and possible solutions for reducing these
Baseline
Resident level data
Age and gender Baseline
Date of admission and discharge and reason for discharge from the facility Baseline and monthly
Diagnosis Baseline and at 12 months
Number and list of regular and PRN medications including dosages Baseline and at 12 months
Emergency Department visit/transfer* Baseline and monthly
Hospital admissions* and length of hospital stay as determined by RACF residents’ records Baseline and monthly
Reason for Emergency Department visit/admission to hospital - as determined by RACF residents’ records Baseline and monthly
Intervention pharmacist activity data
Daily activities and time taken to conduct each activity Daily
*Outpatient appointments & scheduled procedures will not be included in hospital admission/emergency department visit data
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The estimated prevalence of PIM in RACFs at baseline
(60%) was based on previous studies in which the preva-
lence of PIM in Australian RACF residents were re-
ported as 73% in 2018 [16], 49% in 2014 [14] and 56% in
2012 [58].
Data management
Data will be collected from RACFs, by research staff.
RACF staff will facilitate the collection of data from
RACF digital and paper records. Collection of data will
be onto a university laptop which is password-protected.
Resident’s identifying details (e.g. names and date of
birth) will be deleted prior to analysis. Residents will be
given a unique study identifier to link data that will be
stored in a secure place at the RACF. Data will be en-
tered onto a central database developed with Microsoft
Access and stored on the University of Canberra secure
and password-protected data storage system. Access to
the database will be by the key members of the research
team with unique usernames and passwords. The servers
are protected by firewalls and are maintained according
to best practice. After the completion of the study, the
database will remain on the university storage system for
5 years, as per National Health and Medical Research
Council (NHMRC) guidelines.
Statistical analysis
Descriptive statistics will be used to summarise and com-
pare the data at the RACF level in each group at baseline
and at the end of the trial, including primary and second-
ary outcomes as well as additional potential confounder
variables (such as demographic profile, duration of resi-
dency, presence of dementia, Charlson comorbidity index
[59] and number of medical conditions).
Bivariate analyses for group comparisons will use
either t tests or ANOVA for data that are normally dis-
tributed, Mann-Whitney U and Kruskall-Wallis tests for
data that are not normally distributed, or chi-square-
based analysis for categorical outcome data. For within
group comparisons, paired t tests and repeated measures
ANOVAs will be used; if variables are not normally dis-
tributed, the Wilcoxon signed-ranks and Freedman tests
will be used, while the McNemar test will be used for
changes in proportions.
To determine the effect of the intervention on the out-
come measures and the changes over time (between-
within group effects), multilevel modelling methods,
which take into consideration the hierarchical structure
of the data (including clustering within RACF and re-
peated measurement occasions) will be applied. These
modelling methods will include mixed-effects general-
ised linear models (Logistic and Poisson regression
models) for binary and count outcomes as well as
mixed-effects linear models for continuous outcomes
assumed to have a normal distribution, or otherwise
transformed to meet the assumption.
Analysis will be weighted by cluster size as required.
Interactions and adjusting for demographic characteris-
tics and other potential covariates will be included when
deemed necessary. Residents who enter, die or move
from RACFs after baseline data collection will have only
one data point and will be included in the analysis.
When data are missing at random, patterns of missing
data will be evaluated, and potential predictors of miss-
ing responses will be investigated. Methodological at-
tempts to fill in missing data will be extensively explored
and applied as appropriate. These include single imput-
ation approaches (such as regression imputation and
nearest neighbours or hot-deck imputation) and multiple
imputation approaches. Analysis will be conducted using
either SPSS version 26 or STATA version 16. Signifi-
cance level will be set at the usual 5% alpha-level (two-
tailed where applicable). All estimated effects will be re-
ported along with their 95% confidence intervals.
Since the sample size and power calculation have been
devised based on the primary outcome and hypothesis,
the level of adjustment and number of potential covari-
ates to adjust for may be limited by the sample size and
the response rate. Posterior power calculations will be
performed based on available sample size and the sec-
ondary outcomes.
Economic evaluation
A within trial cost consequence followed by a cost-
effectiveness analysis will be conducted. The cost conse-
quence analysis will explore the incremental impact
(compared to the control arm) of the intervention on
the disparate secondary outcomes, providing more infor-
mation to decision makers in addition to a having a
focus on the primary outcome. For the cost-effectiveness
analysis, effectiveness will be measured in terms of the
primary outcome—avoided PIM (reduction of the num-
ber of residents who take at least one PIM). A public
health sector perspective will be used. All resource use
will be valued in 2020/21 Australian dollars without dis-
counting. Total costs for the intervention and control
groups will be calculated, as well as average costs per
participant, incorporating any additional costs relating to
the delivery of the intervention (e.g. additional training,
time that a GP spends on reviewing pharmacist recom-
mendations). Resource use captured during the trial will
include health service utilisation by each participant (ED
visits, hospital admissions, ambulance transfer during
the 12 months of control/intervention period; and medi-
cations used at baseline and at 12 months). Analogous
multilevel modelling described above (controlling for
differences in characteristics of participants and RACF
clusters) will be used to estimate average cost per
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participant for both intervention and control groups.
An incremental cost-effectiveness ratio (ICER) will be
computed by comparing the costs and outcomes of
the intervention and control groups. Results will be
expressed as incremental cost per incremental reduc-
tion in the proportion of residents taking at least one
PIM. Mean estimates will be used, and confidence
values and sensitivity analysis will indicate the robust-
ness and validity of the results and test any assump-
tions used. Uncertainty around the ICER will be
explored using cost-effectiveness acceptability curves.
Fidelity assessment
Fidelity in intervention sites will be assessed using Hasson’s
Conceptual Framework [60], that assesses adherence
against content, coverage, frequency and duration domains
at the cluster level. First, 100% of pharmacist diaries in each
intervention RACF will be assessed and cumulative number
and proportion of activities will be calculated. Second, a
random sample of 10% of resident’s medications reviews
conducted by intervention pharmacists will be assessed by
an experienced pharmacist to determine the appropriate-
ness of medication reviews. Third, interviews with RACF
managers, staff and pharmacists will further explore adher-
ence to the trial activities. Intervention RACFs will be given
a fidelity rating of high/medium/low based on the
assessment.
Trial management
The trial is overseen by the trial management group
comprising chief investigators and the senior programme
manager. The trial is advised by the governance commit-
tee organised by the funder, the ACT Primary Health
Network (PHN) and comprises representative from
RACFs, Pharmaceutical Society of Australian, Pharmacy
Guild of Australia, Calvary hospital, a GP and a con-
sumer representative. Potential protocol modifications
by the trial management group will be communicated to
the governance committee and human research ethics
committees.
Safety evaluation and reporting
RACFs are required to have clinical governance pro-
cesses and complaints procedures in place. Criteria for
monitoring the trial are informed by Stallard [61],
whereby adverse events will be monitored and the trial
ceased if there is evidence of harm. All adverse events
will be entered into an Adverse Event Log and reported
to external clinical consultants to determine whether or
not they are considered causally related to study. For
every adverse event, researchers and external consultants
will provide an assessment of the severity, causal rela-
tionship to the study, outcomes and seriousness of the
event, and document all actions and inform the Human
Research Ethics Committee. In light of the COVID-19
pandemic, the research team will follow all RACF’s
safety protocols and guidelines when they visit RACFs to
ensure the safety of the residents and RACF staff.
Discussion
The initial pilot study [47–51] confirmed the feasibility
of the model, and no adverse events were identified. This
is the first cluster RCT to our knowledge that investi-
gates the effectiveness of integrating pharmacists in
RACFs on improving medication management. The pri-
mary outcome is the appropriateness of prescribing that
in a broader sense may represent an ideal for care [62].
Inappropriate prescribing has become an important pub-
lic health concern worldwide [63] and is also prevalent
in Australian RACFs [14, 16, 58]. In this trial, appropri-
ateness of prescribing is measured using explicit Beers
Criteria [52] which can be readily applied to a large sam-
ple of study participants with a high level of reliability
and reproducibility [63]. Secondary outcomes include
measures such as hospital admission and ED visit that
are important from the public health, aged care industry
and resident perspectives.
Medication management for older residents in RACFs
is sub-optimal [4]. International evidence has demon-
strated that pharmacist-led interventions in RACFs im-
prove the quality use of medicines; however, the
majority of these interventions were conducted by visit-
ing pharmacists on once-off or limited visitation basis
[34, 64]. There is a need for sustainable interventions to
enable system level improvement in medication manage-
ment practices in RACFs.
The study is using a staggered approach to the recruit-
ment and intervention. Due to the impact of the recent
COVID-19 pandemic on RACF’s workforce and opera-
tions, this staggering will provide the facilities with time
to prepare and adapt to recent policy and procedural
changes. These changes may impact on the study out-
comes; for example, there may be changes in the num-
ber of regular healthcare staff in RACFs or residents
may receive fewer GP and other visiting healthcare pro-
fessional visits and this may impact the level of collabor-
ation with pharmacists. Potential restrictions in visiting
RACFs due to COVID-19 pandemic may affect the data
collection processes. On-site pharmacists participating
in this study will have accreditation to conduct medica-
tion review; however, they may be at different level of
experience and skills, which may impact the quality of
pharmacist activities in some RACFs. This will be fur-
ther explored by assessing the fidelity of interventions
that determines whether the intervention was conducted
as planned across the intervention RACFs and includes
an audit on the appropriateness of pharmacists’ medica-
tion reviews. Participating RACFs will be all within ACT
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which is a metropolitan area in Australia; thus, the find-
ings may not be generalisable to RACFs located in rural
and remote areas.
A number of limitations should be noted. PIMs are a
proxy measure for appropriateness of prescribing, which
represents an ideal level of care and is reliable in predict-
ing adverse events [62]. The study does not include mea-
surements of resident focused indicators such as Quality
of Life, noting the difficulties in seeing changes in elderly
frail population. The reporting of secondary outcomes is
based on facility records, which may be under reported.
The study provides important information on clinical
and economical outcomes of the model where on-site
pharmacists are integrated into RACFs’ health care team
to improve medication management. The results will
provide policymakers with recommendations relevant to
the potential further implementation of this model.
Trial status
The study is being conducted according to the trial
protocol version 3 revised on April 7, 2020. Recruitment
began on Oct 28, 2019, and is anticipated to be com-
pleted by July 1, 2020.
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